Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M209Revenue $M0.0Net Margin (%)-406,700.0Z-Score33.4
Enterprise Value $M162EPS $-1.4Operating Margin %-406,700.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-406,700.0Higher ROA y-yY
Price/Book4.810-y EBITDA Growth Rate %-14.6Quick Ratio16.0Cash flow > EarningsY
Price/Sales22,3655-y EBITDA Growth Rate %-12.9Current Ratio16.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-51.5Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-54.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M24.3ROI % (ttm)-56.0Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 8.591%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 8.59-73%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-9.02view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-8.93view
Masterson Nola EDirector 2014-09-15Buy200$14.34-40.24view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-38.12view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-38.39view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-42.75view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-52.12view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-52.47view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-63.95view
Anderson KatherineCFO 2013-02-01Buy1,000$11.89-27.92view

Press Releases about RPRX :

    Quarterly/Annual Reports about RPRX:

    News about RPRX:

    Articles On GuruFocus.com
    comment on RPRX Mar 06 2013 
    Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
    promotes testosteron Jun 22 2011 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
    Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

    More From Other Websites
    REPROS THERAPEUTICS INC. Financials Mar 20 2015
    Repros (RPRX) Incurs Narrower-than-Expected Loss in Q4 - Tale of the Tape Mar 16 2015
    Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results Mar 16 2015
    Repros Therapeutics reports 4Q loss Mar 16 2015
    Repros Therapeutics reports 4Q loss Mar 16 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 16 2015
    Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results Mar 16 2015
    Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog Mar 11 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2015
    Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog Feb 03 2015
    Repros Submits New Drug Application to FDA for Androxal (R) Feb 02 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Feb 02 2015
    Repros Submits New Drug Application to FDA for Androxal (R) Feb 02 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Jan 12 2015
    Repros Initiates Two Phase 2B Uterine Fibroid Studies Dec 29 2014
    Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble Dec 29 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 29 2014
    Repros Initiates Two Phase 2B Uterine Fibroid Studies Dec 29 2014
    Repros Updates Androxal(R) Global Regulatory Status Dec 29 2014
    Court Rules Inventors Correctly Named on Androxal(R) Patents Dec 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK